Posted by Michael Wonder on 19 Jan 2024
US FDA grants mesoblast rare paediatric disease designation for Revascor (Rexlemestrocel-L) in children with congenital heart disease
19 January 2024 - Revascor increases size of left heart chamber and improves surgical outcomes in children with hypoplastic left heart syndrome.
Mesoblast today announced that the US FDA has granted its allogeneic cell therapy Revascor (rexlemestrocel-L) a rare paediatric disease designation following submission of results from the randomised controlled trial in children with hypoplastic left heart syndrome, a potentially life threatening congenital heart condition.
